Ocular Therapeutix (OCUL) Announces NDA Resubmission of DEXTENZA

June 29, 2018 8:00 AM

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found